ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0464

Synovial Inflammation is not Associated With Reoperation in Patients With Rheumatoid Arthritis Undergoing Total Hip or Knee Arthroplasty

Solana Cushing1, Kelsey Gripp2, Edward DiCarlo3, Deanna Jannat-Khah1, Yoshimi Endo3, Jose Rodriguez3, Mark Figgie3, Bella Mehta4 and Susan Goodman3, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, New York, 3Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, 4Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ

Meeting: ACR Convergence 2025

Keywords: Inflammation, rheumatoid arthritis, Synovitis, Total joint replacement

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Reoperations following arthroplasty are a significant burden to patients and surgeons. In patients with RA who receive total hip (THA) or knee (TKA) arthroplasty, radiographic loosening, a common cause of reoperation, has been linked to increased disease activity.1,2 We sought to determine if synovitis in the operated joint at time of THA/TKA was associated with increased risk of reoperation.

Methods: RA patients who underwent primary THA/TKA and a reoperation on the same joint at our institution were identified via the EMR and clinical characteristics were extracted. Synovium specimens from THA/TKA were graded by a board-certified musculoskeletal pathologist for Synovial Lymphocytic Inflammation (SLI), Synovial Lining Hyperplasia (SLH), and Krenn synovitis score. SLI was graded from 0 (none) to 4 (band-like), with SLI 0–1 classified as non-inflammatory and 2–4 as inflammatory. Radiographs preceding reoperation were graded as loose or not loose by a board-certified radiologist based on a combination of periprosthetic lucency and implant position. Kaplan-Meier (KM) survival curves estimated risk of reoperation over time among subjects with a diagnosis of aseptic loosening, implant dislocation, or failure. Log rank tests were performed to assess differences in KM survival curves. Continuous and categorical variables were compared using two-tailed t-tests and Fisher’s exact tests, respectively. Logistic regression models assessed odds of reoperation within 5 years. Analyses were performed using STATA 18.0 with an alpha of 0.05.

Results: Thirty-nine patients meeting eligibility criteria were included; 109 cases were excluded due to secondary surgery on a different joint and 5 because index surgery occurred at another institution. Inflammatory synovium was present in 19 cases. 34 (85%) were female with mean ± SD age of 59± 10 years, BMI 30 ± 8.4 kg/m²; 15 (38.5%) had a loose implant, and 33 (82%) reoperations were revisions (Table 1). Time to reoperation did not differ between inflammatory and non-inflammatory groups (log-rank p-value > 0.05) (Figure 1). Neither diagnosis at reoperation (p-value = 0.24) nor radiographic loosening (53% vs. 25%, p-value = 0.10) differed between groups (Table 2). Inflammatory synovium was not associated with increased odds of reoperation within 5 years (OR 0.98, 95% CI 0.17, 5.83). Neither SLI, SLH, or Krenn score were associated with odds of reoperation within 5 years.

Conclusion: In this small cohort with a low incidence of secondary surgery, synovial inflammation at the time of primary surgery was not associated with increased risk of reoperation. Other factors, including systemic inflammation, may play a role in aseptic loosening and reoperation risk for RA patients undergoing THA or TKA and merit further investigation in a larger cohort. References1. Böhler C, Weimann P, Alasti F, Smolen JS, Windhager R, Aletaha D. Rheumatoid arthritis disease activity and the risk of aseptic arthroplasty loosening. Semin Arthritis Rheum. 2020;50(2):245-251. doi:10.1016/j.semarthrit.2019.07.011 2. Anil U, Singh V, Schwarzkopf R. Diagnosis and Detection of Subtle Aseptic Loosening in Total Hip Arthroplasty. J Arthroplasty. 2022;37(8):1494-1500. doi:10.1016/j.arth.2022.02.060

Supporting image 1Table 1. Demographic, clinical, and histologic features of study patients

Supporting image 2Table 2. Comparison of clinical characteristics at time of reoperation stratified by inflammatory status at primary surgery based on Synovial Lymphocytic Inflammation (SLI) grade

Supporting image 3Figure 1. Kaplan-Meier survival curves for time to reoperation among patients with diagnosis at secondary surgery of implant loosening, dislocation, or failure, grouped by status as inflammatory or non-inflammatory. The proportion of patients undergoing reoperation surgery over time was not statistically different between groups (log-rank p > 0.05).


Disclosures: S. Cushing: None; K. Gripp: None; E. DiCarlo: None; D. Jannat-Khah: AstraZeneca, 11, CytoDyn, 11; Y. Endo: None; J. Rodriguez: ASS ASC Development Network, LLC, 8, BICMD, 2, 8, Exactech, Inc., 2, 9, HS2, LLC, 8, Joint Effort Administrative Services Organization, 8, Restor3d, 2, 9, Smith & Nephew, 2, 9, Wishbone, 8; M. Figgie: Bone Solutions, Inc, 2, Diffusion Rx, Inc., 1, 8, Enovis, 2, 9, HS2, LLC, 8, Icarus Medical, 8, Joint Effort Administrative Services Organization, 8, Mekanika, Inc., 8, Sylke, Inc., 1, 8, Wishbone Medical, 1, 2, 8, 9; B. Mehta: Amgen, 1, Horizon, 1; S. Goodman: Johnson and Johnson, 2, Novartis, 5, Pfizer, 2.

To cite this abstract in AMA style:

Cushing S, Gripp K, DiCarlo E, Jannat-Khah D, Endo Y, Rodriguez J, Figgie M, Mehta B, Goodman S. Synovial Inflammation is not Associated With Reoperation in Patients With Rheumatoid Arthritis Undergoing Total Hip or Knee Arthroplasty [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/synovial-inflammation-is-not-associated-with-reoperation-in-patients-with-rheumatoid-arthritis-undergoing-total-hip-or-knee-arthroplasty/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/synovial-inflammation-is-not-associated-with-reoperation-in-patients-with-rheumatoid-arthritis-undergoing-total-hip-or-knee-arthroplasty/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology